The findings in our study have indicated that HMGB1 expression was increased in patients with necrotizing AP, patients with SIRS, and ICU transfer, suggesting that HMGB1 can be regarded as an important cytokine mediator in the pathogenesis of severe AP, and it is proposed to eventually be an effective therapeutic target for these patients. This evidence concerns the gene HMGB1 and systemic inflammatory response syndrome.